| First Author | Skovsø S | Year | 2022 |
| Journal | Endocrinology | Volume | 163 |
| Issue | 11 | PubMed ID | 36048448 |
| Mgi Jnum | J:335468 | Mgi Id | MGI:7434503 |
| Doi | 10.1210/endocr/bqac144 | Citation | Skovso S, et al. (2022) beta-Cell Cre Expression and Reduced Ins1 Gene Dosage Protect Mice From Type 1 Diabetes. Endocrinology 163(11) |
| abstractText | A central goal of physiological research is the understanding of cell-specific roles of disease-associated genes. Cre-mediated recombineering is the tool of choice for cell type-specific analysis of gene function in preclinical models. In the type 1 diabetes (T1D) research field, multiple lines of nonobese diabetic (NOD) mice have been engineered to express Cre recombinase in pancreatic beta cells using insulin promoter fragments, but tissue promiscuity remains a concern. Constitutive Ins1tm1.1(cre)Thor (Ins1Cre) mice on the C57/bl6-J background have high beta-cell specificity with no reported off-target effects. We explored whether NOD:Ins1Cre mice could be used to investigate beta-cell gene deletion in T1D disease modeling. We studied wild-type (Ins1WT/WT), Ins1 heterozygous (Ins1Cre/WT or Ins1Neo/WT), and Ins1 null (Ins1Cre/Neo) littermates on a NOD background. Female Ins1Neo/WT mice exhibited significant protection from diabetes, with further near-complete protection in Ins1Cre/WT mice. The effects of combined neomycin and Cre knockin in Ins1Neo/Cre mice were not additive to the Cre knockin alone. In Ins1Neo/Cre mice, protection from diabetes was associated with reduced insulitis at age 12 weeks. Collectively, these data confirm previous reports that loss of Ins1 alleles protects NOD mice from diabetes development and demonstrates, for the first time, that Cre itself may have additional protective effects. This has important implications for the experimental design and interpretation of preclinical T1D studies using beta-cell-selective Cre in NOD mice. |
